Skip NavigationSkip to Content

MYH9 Genetic Variants Associated With Glomerular Disease: What Is the Role for Genetic Testing?

  1. Author:
    Kopp, J. B.
    Winkler, C. A.
    Nelson, G. W.
  2. Author Address

    [Kopp, Jeffrey B.] NIDDKD, Kidney Dis Sect, Kidney Dis Branch, NIH, Bethesda, MD 20892 USA. [Winkler, Cheryl A.; Nelson, George W.] Sci Applicat Int Corp, Frederick, MD USA. [Winkler, Cheryl A.; Nelson, George W.] NCI, Ctr Canc Res, NIH, Frederick, MD 21701 USA.;Kopp, JB, NIDDKD, Kidney Dis Sect, Kidney Dis Branch, NIH, 10 Ctr Dr,MSC 1268, Bethesda, MD 20892 USA.;jbkopp@nih.gov
    1. Year: 2010
    2. Date: Jul
  1. Journal: Seminars in Nephrology
    1. 30
    2. 4
    3. Pages: 409-417
  2. Type of Article: Review
  3. ISSN: 0270-9295
  1. Abstract:

    Genetic variation in MYH9, encoding nonmuscle myosin IIA heavy chain, has been associated recently with increased risk for kidney disease. Previously, MY[19 missense mutations have been shown to cause the autosomal-dominant MYH9 (ADM9) spectrum, characterized by large platelets, leukocyte Dohle bodies, and, variably, sensorineural deafness, cataracts, and glomerulopathy. Genetic testing is indicated for familial and sporadic cases that fit this spectrum. By contrast, the MYH9 kidney risk variant is characterized by multiple intronic single nucleotide polymorphisms, but the causative variant has not been identified. Disease associations include human immunodeficiency virus-associated collapsing glomerulopathy, focal segmental glomerulosclerosis, hypertension-attributed end-stage kidney disease, and diabetes-attributed end-stage kidney disease. One plausible hypothesis is that the MYH9 kidney risk variant confers a fragile podocyte phenotype. In the case of hypertension-attributed kidney disease, it remains unclear if the hypertension is a contributing cause or a consequence of glomerular injury. The MYH9 kidney risk variant is strikingly more common among individuals of African descent, but only some will develop clinical kidney disease in their lifetime. Thus, it is likely that additional genes and/or environmental factors interact with the MYH9 kidney risk variant to trigger glomerular injury. A preliminary genetic risk stratification scheme, using two single nucleotide polymorphisms, may estimate lifetime risk for kidney disease. Nevertheless, at present, no role has been established for genetic testing as part of personalized medicine, but testing should be considered in clinical studies of glomerular diseases among populations of African descent. Such studies will address critical questions pertaining to MYH9-associated kidney disease, including mechanism, course, and response to therapy. Semin Nephrol 30:409-417 (C) Published by Elsevier Inc.

    See More

External Sources

  1. DOI: 10.1016/j.semnephrol.2010.06.007
  2. WOS: 000283028700007

Library Notes

  1. Fiscal Year: FY2009-2010
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel